Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double Blind, Double-simulated, Parallel Control of Positive Drug Phase III Clinical Study Evaluating the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Containing Bismuth in Quadruple Therapy for the Eradication of Helicobacter Pylori

NCT07606833 is registered in ClinicalTrials.gov with Xuanzhu Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07606833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07606833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double Blind, Double-simulated, Parallel Control of Positive Drug Phase III Clinical Study Evaluating the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Containing Bismuth in Quadruple Therapy for the Eradication of Helicobacter Pylori
Lead sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
June 10, 2026
Completion date
March 18, 2027
Enrollment
556 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infections